Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Hagiwara S, Takagi H, Kanda D, Sohara N, Kakizaki S, Katakai K, Yoshinaga T, Higuchi T, Nomoto K, Kuwano H, Mori M. Hepatic adenomatosis associated with hormone replacement therapy and hemosiderosis: A case report. World J Gastroenterol 2006; 12(4): 652-655 [PMID: 16489686 DOI: 10.3748/wjg.v12.i4.652]
Hitoshi Takagi, Naondo Sohara, Satoru Kakizaki, Masatomo Mori, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
Kenichi Nomoto, Hiroyuki Kuwano, Department of General Surgical Science, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan
Correspondence to: Hitoshi Takagi, MD, PhD, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa, Maebashi, Gunma 371-8511, Japan. htakagi@med.gunma-u.ac.jp
Telephone: +81-27-220-8127 Fax: +81-27-220-8136
Received: July 4, 2005 Revised: July 28, 2005 Accepted: August 3, 2005 Published online: January 28, 2006
Abstract
We have reported a case of hepatic adenomatosis associated with hormone replacement therapy (estrogen and progesterone) and hemosiderosis caused by excessive blood transfusion for the treatment of chronic myeloid leukemia. A 34-year-old woman was found to have several hepatic tumors on a routine medical examination. The general condition was good. Laboratory studies showed iron overload. Abdominal computed tomography and selective hepatic angiography showed several hypervascular tumors in the right lobe of the liver (up to 20 mm in diameter). Since hepatocellular carcinoma could not be ruled out, subsegmental hepatectomy was performed. Histopathological examination of the surgical specimen showed hepatic adenomatosis with hemosiderosis. Both hormone replacement therapy and iron overload could be the cause of hepatic adenomatosis.